Getinge Interim Report April-June 2026: Good organic growth, high profitability and strong cash flow
"We delivered a strong quarter both financially and operationally with several important key achievements", says Mattias Perjos, President and CEO of Getinge.Sales in Acute Care Therapies increased in most product categories, and the positive trend in consumables for life-supporting ECLS therapy was maintained. Surgical Workflows continued to display good momentum. The situation in Life Science remains mixed − the high-margin category of Sterile Transfer reported double-digit growth for both its order intake and sales. However, the pharma sector’s willingness to invest remains dominated by